CRPC

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

Latest News

TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MDCRPC | March 5, 2025

Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.

Mevrometostat With Enzalutamide: Better Outcomes Compared With Enzalutamide Monotherapy for mCRPC

Emily MenendezCRPC | February 25, 2025

The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.

Final TALAPRO-2 Analysis: Talazoparib Plus Enzalutamide Significantly Improves Survival in HRR-Deficient mCRPC

Brandon TwyfordCRPC | February 21, 2025

Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.

Real-World Outcomes of Lu-PSMA-617 in mCRPC

Jordan Ciuro, MDCRPC | February 14, 2025

New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.

TALAPRO-2: Final OS After First-Line Treatment for Patients With mCRPC

Zachary BessetteCRPC | February 13, 2025

Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.

PSMAfore Data Highlight ctDNA as a Key Predictor of Treatment Outcomes in mCRPC

Emily MenendezCRPC | February 12, 2025

C2D1 ctDNA fraction may be more strongly associated with rPFS and OS than baseline ctDNA fraction.

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer

Localized

nmCRPC

mHSPC

RLT

Prostate Cancer Diagnostics

Prostate Cancer

Localized

nmCRPC

mHSPC

Conference Coverage

ADAPT-BLADDER Cohort 4: A Phase 1/2 Trial of Durvalumab Plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive NMIBC

Noah Hahn, MDUrothelial Carcinoma | February 24, 2025

Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.

Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025

Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.

ASCO GU Prostate Updates: TALAPRO-2 and Other Considerations

Karine Tawagi, MDProstate Cancer | February 24, 2025

Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.

ASCO GU Bladder Updates: EV-302, CheckMate 274, and More

Karine Tawagi, MDUrothelial Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.

ASCO GU Kidney Updates: Triplets, KIM-1, and More

Karine Tawagi, MDRenal Cell Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.

EV-302: Updated Analysis From the Phase 3 Global Study

Guru P. Sonpavde, MDUrothelial Carcinoma | February 24, 2025

Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.